BBA
BIIB icon

Braun-Bostich & Associates’s Biogen BIIB Stock Holding History

Braun-Bostich & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-180
Closed -$51K – 78
2020
Q3 		$51K Sell
180
-306
-63% -$85.3K 0.05% 149
2020
Q2 		$130K Hold
486
– – 0.13% 91
2020
Q1 		$143K Hold
486
– – 0.18% 88
2019
Q4 		$143K Buy
+486
New +$135K 0.14% 101
2019
Q3 		– Sell
-908
Closed -$212K – 113
2019
Q2 		$212K Sell
908
-758
-45% -$175K 0.22% 92
2019
Q1 		$394K Sell
1,666
-418
-20% -$132K 0.41% 64
2018
Q4 		$627K Buy
2,084
+2
+0.1% +$638 0.67% 44
2018
Q3 		$736K Buy
2,082
+42
+2% +$14.5K 0.71% 43
2018
Q2 		$592K Sell
2,040
-20
-1% -$5.62K 0.59% 54
2018
Q1 		$564K Buy
2,060
+136
+7% +$42.2K 0.49% 65
2017
Q4 		$613K Buy
+1,924
New +$617K 0.52% 59

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Braun-Bostich & Associates's BIIB Position: Q4 2020 in Review

Braun-Bostich & Associates sold out of Biogen (BIIB) in Q4 2020, closing a stake of 180 shares — an estimated $51K sold.

Braun-Bostich & Associates first reported a position in BIIB in Q4 2017 and held it in 11 quarters. The position peaked at $736K in Q3 2018. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

  • Braun-Bostich & Associates reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
  • Braun-Bostich & Associates sold 180 Biogen shares in Q4 2020, an estimated $51K.
  • Braun-Bostich & Associates first reported a position in Biogen in Q4 2017 and held it in 11 quarters.
  • Braun-Bostich & Associates's Biogen position peaked at $736K in Q3 2018.
  • 1,062 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Braun-Bostich & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.